AstraZeneca’s Baxfendy Approval Isn’t a Hypertension Win — It’s a $40 Billion Market Wedge
FDA approved AstraZeneca's baxdrostat (Baxfendy) on May 18, 2026 — the first aldosterone synthase inhibitor for hypertension. Here's what...
pulmonary hypertension
Medtronic’s $100M Bet on Pulnovo Isn’t About Pulmonary Hypertension — It’s About Owning the Next Cardiovascular Platform
Medtronic's strategic investment in Pulnovo Medical's oversubscribed $100M round signals a quiet land grab in pulmonary hypertension and heart...